We've found 39 total result s for "Solid Tumor".

Lamivudine for Solid Tumors

Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors. Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System. Primary Objective: For Phase 1b to determine the safety and tolerabilit...

Age: 18 years - 66+

Gender: All

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination w...

Age: 18 years - 66+

Gender: All

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are: - To check the safety of ASP1002 in people with certain solid tumors. - To check if the people can tolerate ASP1002. - To find a suitable dose of ASP1002. This study will be in 2 parts. In Part 1, different small groups of ...

Age: 18 years - 66+

Gender: All

Study of DF9001 in Patients With Advanced Solid Tumors

DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various t...

Age: 18 years - 66+

Gender: All

A Study of YL201 in Patients with Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the M...

Age: 18 years - 66+

Gender: All

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate...

Age: 18 years - 66+

Gender: All